Sorry, you need to enable JavaScript to visit this website.

A Study to Assess the Efficacy and Safety of PF-06650833, PF-06651600, and Tofacitinib Alone and in Combination in Active Rheumatoid Arthritis

A Study to Assess the Efficacy and Safety of PF-06650833, PF-06651600, and Tofacitinib Alone and in Combination in Active Rheumatoid Arthritis. A 24-Week Randomized, Double-Blind, Parallel Group, Active Comparator, Multicenter Study to Assess the Efficacy and Safety of PF-06650833, PF- 06651600 (Ritlecitinib) and Tofacitinib Alone and in Combination in Participants With Moderately-Severely Active Rheumatoid Arthritis With an Inadequate
Response to Methotrexate.

Category & Conditions: Immune System Diseases and Conditions
Medicine: PF-06650833 + ritlecitinib + Xeljanz (tofacitinib)
ClinicalTrials.gov Identifier (NCT): NCT04413617
Protocol ID: B7921023
PrintDownload
Open Plain Language Summary Result: Click here